No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical aesthetics, renal care, respiratory health, and gastrointestinal support. Beyond these, the company also provides oral medications, topical treatments, and an array of hygiene products like hand, mechanical, and skin disinfectants, alongside body lotions. Additionally, Panion & Bf Biotech supplies veterinary health solutions, notably surgical and dermatological prescriptions for animals. Established in 1976, the company maintains its corporate headquarters in Taipei, Taiwan.
www.pbf.com.twNo one on the platform currently holds 1760.TW.
No tracked institution reports a position in 1760.TW as of their last filing.
No one on the platform has traded 1760.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.3% | 6.6% | 9.7% | — | — | — |
| Rev. Growth % | 1.7% | 5.6% | ||||
| Profit Margin % | 9.2% | 6.5% | 7.2% | |||
| Free Cash Flow Margin % | 7.3% | 7.9% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | +5.4% | $2.51 | $2.51–$2.51 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $0.49 | $0.46 | -6.4% |
| 2026-05-12 | $0.43 | $0.60 | +39.5% |
| 2026-03-04 | $0.43 | $0.57 | +32.6% |
| 2025-11-11 | $0.41 | $0.88 | +114.6% |
| 2025-08-12 | $0.43 | $0.44 | +2.3% |
| 2025-05-12 | $0.31 | $0.33 | +6.5% |
| 2025-03-05 | $0.39 | $0.38 | -2.6% |
| 2024-11-12 | $0.37 | $0.32 | -13.5% |
| $19.10 |
| +0.26% |
| $6.3B |
| — |
| 4174.TWOOBI Pharma, Inc. | $26.45 | +1.73% | $3.5B | — |
| 4726.TWOMycenax Biotech Inc. | $22.50 | -0.44% | $4.7B | — |
Source: Financial Modeling Prep · peers by sector/industry